Fortress Biotech (Fortress Biotech) Margin of Safety % (DCF Dividends Based) : N/A (As of May. 14, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Fortress Biotech Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Fortress Biotech's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

Competitive Comparison of Fortress Biotech's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Fortress Biotech's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fortress Biotech's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Margin of Safety % (DCF Dividends Based) falls into.

Fortress Biotech Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Fortress Biotech (Fortress Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (NAS:FBIO) » Definitions » Margin of Safety % (DCF Dividends Based)

Comparable Companies

Traded in Other Exchanges

FBIOP.PFD:USA CNB0.PFD:Germany

Address

1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154

Website

https://www.fortressbiotech.com

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Executives

Rosenwald Lindsay A Md	director, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN	375 PARK AVE, NEW YORK NY 10152
Lucy Lu	director	THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
David Jin	officer: Chief Financial Officer	C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036
Dov Klein	director	C/O FORTRESS BIOTECH, INC., 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
Robyn Hunter	officer: Chief Financial Officer	95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eric K Rowinsky	director	IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Malcolm Hoenlein	director	750 LEXINGTON AVENUE, NEW YORK NY 10022
Michael S Weiss	director, 10 percent owner, officer: EXECUTIVE VICE CHAIRMAN	750 LEXINGTON AVE, NEW YORK NY 10022
J Jay Lobell	director	365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Jimmie Harvey	director	3741 EAST FAIRWAY DRIVE, BIRMINGHAM AL 35213
Kevin Lorenz	director	C/O NUVEEN, 333 W. WACKER DR., CHICAGO IL 60606
George Avgerinos	officer: SVP, Biologics Operations	C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Kevin Horgan	other: Former Chief Medical Officer	C/O SOLIGENIX, INC., 29 EMMONS DRIVE, STE. C-10, PRINCETON NJ 08540
David Jonathan Barrett	director	ONE PENN PLAZA, SUITE 2514, NEW YORK NY 10119
Harlan F Weisman	director	C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803